Last reviewed · How we verify

Live attenuated human rotavirus vaccine

GlaxoSmithKline · Phase 3 active Biologic

Live attenuated human rotavirus vaccine is a Live attenuated vaccine Biologic drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Prevention of rotavirus gastroenteritis in infants and young children.

A live attenuated rotavirus vaccine stimulates the immune system to produce antibodies and cellular immunity against rotavirus by introducing a weakened form of the virus.

A live attenuated rotavirus vaccine stimulates the immune system to produce antibodies and cellular immunity against rotavirus by introducing a weakened form of the virus. Used for Prevention of rotavirus gastroenteritis in infants and young children.

At a glance

Generic nameLive attenuated human rotavirus vaccine
SponsorGlaxoSmithKline
Drug classLive attenuated vaccine
ModalityBiologic
Therapeutic areaImmunology / Infectious Disease
PhasePhase 3

Mechanism of action

The vaccine contains a live but weakened (attenuated) rotavirus strain that replicates in the intestinal tract without causing severe disease. This triggers both humoral (antibody) and cell-mediated immune responses, priming the immune system to recognize and neutralize wild-type rotavirus upon natural exposure. The attenuated virus is designed to be immunogenic while maintaining a safety profile suitable for infants.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Live attenuated human rotavirus vaccine

What is Live attenuated human rotavirus vaccine?

Live attenuated human rotavirus vaccine is a Live attenuated vaccine drug developed by GlaxoSmithKline, indicated for Prevention of rotavirus gastroenteritis in infants and young children.

How does Live attenuated human rotavirus vaccine work?

A live attenuated rotavirus vaccine stimulates the immune system to produce antibodies and cellular immunity against rotavirus by introducing a weakened form of the virus.

What is Live attenuated human rotavirus vaccine used for?

Live attenuated human rotavirus vaccine is indicated for Prevention of rotavirus gastroenteritis in infants and young children.

Who makes Live attenuated human rotavirus vaccine?

Live attenuated human rotavirus vaccine is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

What drug class is Live attenuated human rotavirus vaccine in?

Live attenuated human rotavirus vaccine belongs to the Live attenuated vaccine class. See all Live attenuated vaccine drugs at /class/live-attenuated-vaccine.

What development phase is Live attenuated human rotavirus vaccine in?

Live attenuated human rotavirus vaccine is in Phase 3.

What are the side effects of Live attenuated human rotavirus vaccine?

Common side effects of Live attenuated human rotavirus vaccine include Diarrhea, Vomiting, Fever, Irritability.

Related